VTYX Stock Rises on Strategic Equity Investment Deal With SNY

Zacks09-24

Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi SNY. Per the terms of the deal, ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470411938?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OKs2Umbh_jq1JHRq6tWCew--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c1d0d60d32130a1e1beb497a426ea24","is_english":true,"pubTime":"2024-09-24 22:24","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2470411938","market":"us","top_or_hot":-1,"title":"VTYX Stock Rises on Strategic Equity Investment Deal With SNY","media":"Zacks","content":"<div>\n<p>Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi SNY. Per the terms of the deal, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vtyx-stock-rises-strategic-equity-142400808.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>VTYX Stock Rises on Strategic Equity Investment Deal With SNY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVTYX Stock Rises on Strategic Equity Investment Deal With SNY\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-24 22:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/vtyx-stock-rises-strategic-equity-142400808.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi SNY. Per the terms of the deal, ...</p>\n\n<a href=\"https://finance.yahoo.com/news/vtyx-stock-rises-strategic-equity-142400808.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0256863902.USD","symbol_name":"ALLIANZ US EQUITY \"AT\" (USD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/vtyx-stock-rises-strategic-equity-142400808.html","article_id":"2470411938","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OKs2Umbh_jq1JHRq6tWCew--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/0c1d0d60d32130a1e1beb497a426ea24"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470411938","pubTimestamp":1727187840,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi SNY. Per the terms of the deal, Sanofi will buy 70,601 of Ventyx’s Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock.The proceeds from this investment are anticipated to enhance Ventyx’s cash reserves. With the addition of these funds, the combined total of current cash, cash equivalents and marketable securities is expected to support the company's planned operations until at least the second half of 2026.VTYX Grants SNY Exclusive Rights to Investigational Drug. Ventyx believes that this strategic deal with Sanofi underscores the potential of VTX3232 to offer a disease-modifying treatment for CNS indications with significant unmet medical needs. The company will also be able to utilize Sanofi","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","BK4588":"碎股","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","SNY":"赛诺菲安万特","IE00BFXG1179.USD":"BNY MELLON U.S. EQUITY INCOME \"B\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","NVO":"诺和诺德","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","BK4532":"文艺复兴科技持仓","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","BK4581":"高盛持仓","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","BK4215":"住宅房地产投资信托","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4534":"瑞士信贷持仓","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","VTYX":"Ventyx Biosciences, Inc.","RA":"Brookfield Real Assets Income Fund Inc.","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","CNS":"科恩-斯蒂尔斯金融","EQR":"资产住宅公司","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LLY":"礼来","LU0385154629.USD":"贝莱德营养科学基金A2"},"translate_title":"VTYX股价因与SNY达成战略股权投资协议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTYX":1,"SNY":1,"RA":1,"CNS":1,"EQR":1,"NVO":0.6,"LLY":0.6},"content_text":"Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million strategic investment agreement with Sanofi SNY. Per the terms of the deal, Sanofi will buy 70,601 of Ventyx’s Series A non-voting convertible preferred stock for $3.8243 per share. Per the press release, each acquired preferred stock will initially be converted into 100 shares of common stock. \nThe proceeds from this investment are anticipated to enhance Ventyx’s cash reserves. With the addition of these funds, the combined total of current cash, cash equivalents and marketable securities is expected to support the company's planned operations until at least the second half of 2026.\nVTYX Grants SNY Exclusive Rights to Investigational Drug\nIn return for the $27 million equity investment, Ventyx has granted Sanofi the exclusive opportunity to first negotiate certain rights related to the clinical programs of VTYX’s investigational candidate, VTX3232. Notably, VTX3232 is an oral, selective, central nervous system (CNS)-penetrant NLRP3 inhibitor, which is being developed for various neuroinflammatory and neurodegenerative indications, including Parkinson’s disease, cardiometabolic disease, Alzheimer’s disease and multiple sclerosis.\nVentyx believes that this strategic deal with Sanofi underscores the potential of VTX3232 to offer a disease-modifying treatment for CNS indications with significant unmet medical needs. The company will also be able to utilize Sanofi’s large resources and prowess in developing treatments for immunological and inflammatory diseases.\nYear to date, shares of Ventyx have lost 0.4% compared with the industry‘s 1.5% decline.\nImage Source: Zacks Investment Research\nVTYX’s Development Programs for VTX3232\nCurrently, Ventyx is developing VTX3232 for the treatment of Parkinson’s disease and obesity. In early September, the company initiated a phase IIa study to evaluate VTX3232 in patients with early Parkinson’s disease. Top-line results are expected in 2025.\nVentyx is also currently gearing up to initiate a separate 12-week phase II study of VTX3232 by the end of 2024 in patients with obesity and additional cardiovascular and cardiometabolic risk factors. The planned study will assess the impact of VTX3232 on key inflammatory biomarkers and weight change, both as a monotherapy and in combination with a GLP-1 receptor agonist (RA). Top-line data from this obesity study of VTX3232 is also expected in 2025.\n\nVentyx Biosciences, Inc. Price and Consensus\n\nVentyx Biosciences, Inc. price-consensus-chart | Ventyx Biosciences, Inc. Quote\n\nThe obesity sector has garnered much interest in 2024 due to its huge untapped market potential. Several biotech firms are competing fiercely to enter this market and are evaluating candidates for the obesity indication.\nThe obesity market is currently dominated by two large drugmakers, Eli Lilly LLY and Novo Nordisk NVO, with their respective obesity drugs Zepbound (tirzepatide) and Wegovy (semaglutide). Despite having approved drugs in this space, LLY and NVO have been unable to cope with existing demand. Both companies have been investing heavily to ramp up production to meet increasing demand.\nHowever, both NVO’s Wegovy and LLY’s Zepbound are administered as weekly injections. Novo Nordisk, Lilly and some other drugmakers are making oral medicines with different mechanisms of action for obesity, which can improve patient convenience.\nOther Programs in VTYX’s Clinical-Stage Pipeline\nApart from VTX3232, there are three early to mid-stage candidates in Ventyx’s pipeline, VTX2735 (peripheral NLRP3 inhibitor), VTX002 (S1P1R modulator) and VTX958 (TYK2 inhibitor). While VTX2735 is being evaluated to treat cardiovascular and other systemic inflammatory diseases, VTX002 and VTX958 are under development for ulcerative colitis and Crohn’s disease, respectively.\nVTYX’s Zacks Rank\nVentyx currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nSanofi (SNY) : Free Stock Analysis Report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nVentyx Biosciences, Inc. (VTYX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470411938"}